Business Context and Reporting Period
Company: Aquestive Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 14, 2025
Principal Event: Entry into a Material Definitive Agreement for an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 21,250,000 shares of Common Stock.
- Offering Price: $4.00 per share.
- Gross Proceeds: $85.0 million (expected).
- Net Proceeds: Not explicitly stated; gross proceeds are after deducting underwriting discount and estimated offering expenses.
- Underwriters: Leerink Partners LLC, Cantor Fitzgerald & Co., and Oppenheimer & Co. Inc.
- Expected Closing Date: August 15, 2025.
Material Changes and Use of Proceeds
This filing represents a significant capital raise event rather than a periodic financial performance report. The material change is the execution of the Underwriting Agreement. The Company intends to use the net proceeds, combined with existing cash and cash equivalents, for the following purposes:
- Advancing the launch and commercialization of Anaphylm™ (epinephrine) Sublingual Film for severe life-threatening allergic reactions, subject to FDA approval.
- Working capital, capital expenditures, and general corporate purposes.
- Runway Extension: Management believes the proceeds will fund planned operating expenses and capital expenditures into 2027.
Guidance, Outlook, and Risks
Outlook: The Company anticipates the offering will close on August 15, 2025, subject to customary conditions. The capital raise is strategic to support the commercialization timeline of its lead product candidate, Anaphylm™.
Risks and Contingencies:
- Regulatory Approval: Commercialization of Anaphylm™ is contingent upon United States Food and Drug Administration (FDA) approval.
- Forward-Looking Statements: The report contains forward-looking statements regarding the completion, timing, and size of the offering. Actual results may differ materially due to market conditions and the satisfaction of closing conditions.
- Market Risks: General risks associated with market conditions are referenced in the Company's Form 10-K for the fiscal year ended December 31, 2024.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received after all expenses.
- Confirm the status of the FDA application for Anaphylm™ (epinephrine) Sublingual Film.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification rights and covenants.
- Assess the Company's current cash balance to validate the "into 2027" runway projection.
- Check for any lock-up agreements or restrictions on the sale of shares by existing shareholders.